Formycon AG Revenue and Competitors

Planegg, Ger

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Formycon AG's estimated annual revenue is currently $32.5M per year.(i)
  • Formycon AG's estimated revenue per employee is $169,531

Employee Data

  • Formycon AG has 192 Employees.(i)
  • Formycon AG grew their employee count by 12% last year.

Formycon AG's People

NameTitleEmail/Phone
1
VP Clinical Development & OperationsReveal Email/Phone
2
Head Functional CharacterizationReveal Email/Phone
3
Head Drug Product Process DevelopmentReveal Email/Phone
4
Senior Director Operations & commercial Qualified PersonReveal Email/Phone
5
Associate Director ProcurementReveal Email/Phone
6
Director Clinical OperationsReveal Email/Phone
7
Quality Assurance Manager - External PartnersReveal Email/Phone
8
Senior Manager Clinical OperationsReveal Email/Phone
9
IT Compliance ManagerinReveal Email/Phone
10
Clinical Development ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.6M19212%N/AN/A
#2
$14.3M8311%N/AN/A
#3
$11.5M7410%N/AN/A
#4
N/A5969%N/AN/A
#5
N/A5893%N/AN/A
#6
$27.4M17733%N/AN/A
Add Company

What Is Formycon AG?

Who we are Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207 About Biosimilars: Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion. Contact: Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 info@formycon.com

keywords:N/A

N/A

Total Funding

192

Number of Employees

$32.5M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$116M58052%N/A
#2
$162.7M121933%N/A